Details
Stereochemistry | ACHIRAL |
Molecular Formula | Fe.S2 |
Molecular Weight | 119.975 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Fe++].[S-][S-]
InChI
InChIKey=NIFIFKQPDTWWGU-UHFFFAOYSA-N
InChI=1S/Fe.S2/c;1-2/q+2;-2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502
Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Primary | Ferro Sanol Duodenal Approved UseFerro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia. |
|||
PubMed
Title | Date | PubMed |
---|---|---|
[FERROUS ASPARTATE IN THERAPY]. | 1964 Jan 1 |
|
Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe. | 1997 Oct |
|
The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia. | 2010 Dec |
|
Tolerability of different oral iron supplements: a systematic review. | 2013 Apr |
|
Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows. | 2013 Jul |
|
Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example. | 2017 Jul 5 |
|
Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes. | 2017 Mar 13 |
|
Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle. | 2017 May 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/ferrous-salts.html
Unknown
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C011342
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
86471
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
1544140
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
132N09W4PR
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
100000172235
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
DTXSID801014311
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
215-167-7
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
ALTERNATIVE | |||
|
1317-66-4
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
ALTERNATIVE | |||
|
132N09W4PR
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
123110
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
235-106-8
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
12068-85-8
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
PRIMARY | |||
|
1309-36-0
Created by
admin on Sat Dec 16 06:18:05 GMT 2023 , Edited by admin on Sat Dec 16 06:18:05 GMT 2023
|
ALTERNATIVE |
ACTIVE MOIETY
SUBSTANCE RECORD